Mechanisms of Mesenchymal Stem Cells for Autoimmune Disease Treatment

2019 ◽  
pp. 27-44 ◽  
Author(s):  
Nazmul Haque ◽  
Thamil Selvee Ramasamy ◽  
Noor Hayaty Abu Kasim
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Autoimmune Disease ◽  
Disease Treatment

Migration of Human Mesenchymal Stem Cells is Stimulated by Low Shear Stress via MAPK Signaling

2012 ◽  
Author(s):  
Lin Yuan ◽  
Naoya Sakamoto ◽  
Guanbin Song ◽  
Masaaki Sato
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Human Mesenchymal Stem Cells ◽  
Mapk Signaling ◽  
Disease Treatment ◽  
Differentiation Potential ◽  
Multipotent Stem Cells ◽  
Low Shear Stress ◽  
Multipotent Differentiation ◽  
And Migration

Mesenchymal stem cells (MSCs) represent as multipotent stem cells which hold the abilities of self-renewal and give rise to cells of diverse lineages [1]. With their remarkable combination of multipotent differentiation potential and low immunogenicity, MSCs are considered to be an attractive candidate for cell-based tissue repair and regenerative tissue engineering [2, 3]. Increasing number of studies has demonstrated that mobilization and migration of injected MSCs to the damaged tissues is a key step for these cells to participate in disease treatment and tissue regeneration [4, 5].

Prospects for the application of mesenchymal stem cells in Alzheimer's disease treatment

Life Sciences ◽  
2019 ◽  
Vol 231 ◽  
pp. 116564 ◽  
Author(s):  
Forough Chakari-Khiavi ◽  
Sanam Dolati ◽  
Aref Chakari-Khiavi ◽  
Hossein Abbaszadeh ◽  
Leili Aghebati-Maleki ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Disease Treatment

Mesenchymal Stem Cells in Autoimmune Disease

2004 ◽  
Vol 13 (5) ◽  
pp. 463-472 ◽  
Author(s):  
Nagwa S. El-Badri ◽  
Akhil Maheshwari ◽  
Paul R. Sanberg
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Autoimmune Disease

scholarly journals Mesenchymal stem cells from amnion and amniotic fluid in the bovine

Reproduction ◽  
2013 ◽  
Vol 145 (4) ◽  
pp. 391-400 ◽  
Author(s):  
B Corradetti ◽  
A Meucci ◽  
D Bizzaro ◽  
F Cremonesi ◽  
A Lange Consiglio
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Amniotic Fluid ◽  
Cellular Therapy ◽  
Low Cost ◽  
Clinical Applications ◽  
Disease Treatment ◽  
First Time ◽  
Bovine Species ◽  
Proliferative Ability

Amnion and amniotic fluid (AF) are noncontroversial and inexhaustible sources of mesenchymal stem cells (MSCs) that can be harvested noninvasively at low cost. As in humans, also in veterinary field, presumptive stem cells derived from these tissues reveal as promising candidates for disease treatment, specifically for their plasticity, their reduced immunogenicity, and high anti-inflammatory potential. The aim of this work is to obtain and characterize, for the first time in bovine species, presumptive MSCs from the epithelial portion of the amnion (AECs) and from the AF (AF-MSCs) to be used for clinical applications. AECs display a polygonal morphology, whereas AF-MSCs exhibit a fibroblastic-like morphology only starting from the second passage, being heterogeneous during the primary culture. For both lines, the proliferative ability has been found constant over the ten passages studied and AECs show a statistically lower (P<0.05) doubling time with respect to AF-MSCs. AECs express MSC-specific markers (ITGB1(CD29),CD44,ALCAM(CD166),ENG(CD105), andNT5E(CD73)) from P1 to P3; in AF-MSCs, onlyITGB1,CD44, andALCAMmRNAs are detected;NT5Eis expressed from P2 andENGhas not been found at any passage. AF-MSCs and AECs are positive for the pluripotent markers (POU5F1(OCT4) andMYC(c-Myc)) and lack of the hematopoietic markers. When appropriately induced, both cell lines are capable of differentiating into ectodermal and mesodermal lineages. This study contributes to reinforce the emerging importance of these cells as ideal tools in veterinary medicine. A deeper evaluation of the immunological properties needs to be performed in order to better understand their role in cellular therapy.

Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis

2007 ◽  
Vol 67 (4) ◽  
pp. 443-449 ◽  
Author(s):  
J Larghero ◽  
D Farge ◽  
A Braccini ◽  
S Lecourt ◽  
A Scherberich ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Systemic Sclerosis ◽  
Autoimmune Disease ◽  
Healthy Donor ◽  
Large Scale ◽  
Mononuclear Cells ◽  
Differentiation Potential

Background:Mesenchymal stem cells (MSCs) have a potential immunomodulatory role in autoimmune disease; however, the qualitative properties and haematopoietic support capacity of MSCs derived from patients with autoimmune disease is unclear.Objectives:To further characterise phenotypically and functionally bone marrow (BM)-derived MSCs from patients with systemic sclerosis (SSc).Methods:Key parameters of BM-derived MSC function and phenotype were assessed in 12 patients with SSc and compared with 13 healthy normal controls. The parameters included the ability to: form colony-forming unit fibroblasts (CFU-F), differentiate along the adipogenic and osteogenic lineages, express cell surface antigens defining the MSCs population, support normal haematopoiesis and suppress in vitro lymphocyte proliferation induced by either anti-CD3∊ plus anti-CD28 monoclonal antibodies or the mixed lymphocyte reaction.Results:SSc MSCs were shown to have a similar characteristic phenotype, capacities to form CFU-F and to differentiate along adipogenic and osteogenic lineages as those of healthy donor MSCs. The ability of SSc MSCs to support long-term haematopoiesis was also identical to that of controls. Both healthy donor and SSc BM MSCs reduced the proliferation of autologous and allogeneic peripheral blood mononuclear cells in a cell number dependent fashion.Conclusions:These results show that BM-derived MSCs from patients with SSc under the described culture conditions exhibit the same phenotypic, proliferative, differentiation potential and immunosuppressive properties as their healthy counterparts and could therefore be considered in an autologous setting. Further studies are needed to ensure the quality and safety of large-scale expansion of patient MSCs prior to their potential use in clinical trials.

scholarly journals Human Olfactory Mesenchymal Stem Cells Are a Novel Candidate for Neurological Autoimmune Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Chongjun Xiao ◽  
Di Lu ◽  
Jinshuo Chen ◽  
Xiaoyan Chen ◽  
Huizhu Lin ◽  
...  
Keyword(s):  
Stem Cells ◽  
T Cells ◽  
Mesenchymal Stem Cells ◽  
Treatment Group ◽  
Autoimmune Disease ◽  
Functional Recovery ◽  
Therapeutic Option ◽  
Control Group ◽  
Immune Disorder ◽  
Ifn Γ

Background: Human olfactory mesenchymal stem cells (OMSC) have become a novel therapeutic option for immune disorder or demyelinating disease due to their immunomodulatory and regenerative potentials. However, the immunomodulatory effects of OMSC still need to be elucidated, and comparisons of the effects of different MSCs are also required in order to select an optimal cell source for further applications.Results: In animal experiments, we found neural functional recovery and delayed EAE attack in the OMSC treatment group. Compared with umbilical cord–derived mesenchymal stem cells (UMSC) treatment group and the control group, the OMSC treatment group had a better neurological improvement, lower serum levels of IFN-γ, and a lower proportion of CD4+IFN-γ+ T splenic lymphocyte. We also observed OMSC effectively suppressed CD4+IFN-γ+ T cell proportion in vitro when co-cultured with human peripheral blood–derived lymphocytes. The OMSC-mediated immunosuppressive effect on human CD4+IFN-γ+ T cells was attenuated by blocking cyclooxygenase activity.Conclusion: Our results suggest that OMSC treatment delayed the onset and promoted the neural functional recovery in the EAE mouse model possibly by suppressing CD4+IFN-γ+ T cells. OMSC transplantation might become an alternative therapeutic option for neurological autoimmune disease.

scholarly journals Detection of MicroRNAs in Extracellular Vesicles Secreted by Umbilical Cord-derived Mesenchymal Stem Cells

2021 ◽  
Vol 37 (3) ◽  
Author(s):  
Nguyen Thu Huyen ◽  
Duong Minh Chau ◽  
Do Thi Xuan Phuong ◽  
Nguyen Thanh Liem ◽  
Than Thi Trang Uyen
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Extracellular Vesicles ◽  
Potential Role ◽  
Culture Media ◽  
Therapeutic Effects ◽  
Potential Candidate ◽  
Disease Treatment

Extracellular vesicles (EVs) are emerging as a potential candidate for disease treatment due to their bioactive cargoes. Recently, mesenchymal stem cells (MSC)-derived EVs have shown their capacity to replace parental cells as their similar functions to MSCs. The therapeutic effects of EVs depend on their cargo, such as DNA, miRNA, proteins, and lipids. In this study, we expanded umbilical cord-derived MSCs (UCMSCs) for EV release. Additionally, we evaluated the expression level of several microRNAs in three EV populations, including apoptotic bodies (AB), microvesicles (MV), and exosomes (EX). Results showed that UCMSCs released three EV types: AB, MV, and EX into culture media. The three EV populations were different in morphology and size. Three EVs were detected to carry microRNAs, such as hsa-miR-320, hsa-miR-181b, and hsa-miR-140. Among these microRNAs, hsa-miR-140 expressed with the greatest level, followed by hsa-miR-181b and hsa-miR-320. The results of this study provide more knowledge about UCMSC-derived EV miRNAs in addition to reveal the potential role of UCMSC-EVs associated with detected miRNAs.

scholarly journals Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis

2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Ming Liu ◽  
Xiansheng Zeng ◽  
Junli Wang ◽  
Zhiping Fu ◽  
Jinsong Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Autoimmune Disease ◽  
Lung Fibrosis ◽  
Human Autoimmune Disease
Sign in / Sign up

Export Citation Format

Share Document